Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kirin-Kyowa Hakko Merger Seen Speeding Drug Industry Consolidation (Japan)

This article was originally published in PharmAsia News

Executive Summary

Kirin Holdings Co. and Kyowa Hakko Kogyo Co. recently announced plans to merge their pharmaceutical operations. This partnership is the latest in a growing group of Japanese pharmaceutical companies teaming up to stay afloat in the country's increasingly tight market. In an effort to lower healthcare costs, the Japanese government says its goal is for generic drugs to represent 30 percent of pharmaceutical sales by 2012. Because of this initiative, many Japanese companies are also attempting to expand to international markets. Setting up overseas operations can be a costly process. Several of Japan's largest drug-makers, including Astellas Pharma Inc. and Daiichi Sankyo Co. were created to satisfy their growing need for funding. As for Kirin and Kyowa, the two companies seem to be a good match because they both have the capabilities to create antibody-based treatments. These drugs offer a promising new method for fighting cancer and other diseases while decreasing the risk of side effects. (Click here for more - May Require Paid Subscription

You may also be interested in...

Japan's Kyowa Hakko Posts Strong Profits for Fiscal Year 2007

TOKYO - Kyowa Hakko Kogyo Co. said the fiscal year ended March 31 saw strong earnings compared to previous years. The Tokyo-based company also said fiscal year 2007 was the final year of a three-year, medium-term business plan and that the company exceeded plan targets "significantly" for sales and operating income

QUOTED. 24 November 2020. Kees Wesdorp.

Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.

Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue

Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts